Literature DB >> 28196306

Effects of isoflurane anesthesia and intravenous morphine self-administration on regional glucose metabolism ([18 F]FDG-PET) of male Sprague-Dawley rats.

Thomas Y Park1,2, Kevin S Nishida1,2, Colin M Wilson3,4, Shalini Jaiswal3, Jessica Scott3, Andrew R Hoy3,5, Reed G Selwyn3,4,5, Bernard J Dardzinski3,5, Kwang H Choi1,2,6,7.   

Abstract

Although certain drugs of abuse are known to disrupt brain glucose metabolism (BGluM), the effects of opiates on BGluM are not well characterized. Moreover, preclinical positron emission tomography (PET) studies anesthetize animals during the scan, which limits clinical applications. We investigated the effects of (i) isoflurane anesthesia and (ii) intravenous morphine self-administration (MSA) on BGluM in rats. Jugular vein cannulated adult male Sprague-Dawley rats self-administered either saline (SSA) or morphine (0.5 mg/kg/infusion, 4 h/day for 12 days). All animals were scanned twice with [18 F]-fluoro-deoxy-glucose (FDG)-PET/CT at a baseline and at 2-day withdrawal from self-administration. After the IV injection of FDG, one batch of animals (n = 14) was anesthetized with isoflurane and the other batch (n = 16) was kept awake during the FDG uptake (45 min). After FDG uptake, all animals were anesthetized in order to perform a PET/CT scan (30 min). Isoflurane anesthesia, as compared to the awake condition, reduced BGluM in the olfactory, cortex, thalamus, and basal ganglia, while increasing BGluM in the midbrain, hypothalamus, hippocampus, and cerebellum. Morphine self-administered animals exhibited withdrawal signs (piloerection and increased defecation), drug seeking, and locomotor stimulation to morphine (0.5 mg/kg) during the 2 day withdrawal. The BGluM in the striatum was increased in the MSA group as compared to the SSA group; this effect was observed only in the isoflurane anesthesia, not the awake condition. These findings suggest that the choice of the FDG uptake condition may be important in preclinical PET studies and increased BGluM in the striatum may be associated with opiate seeking in withdrawal.
© 2017 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  brain energy metabolism; brain imaging; drug self-administration; opiate addition

Mesh:

Substances:

Year:  2017        PMID: 28196306     DOI: 10.1111/ejn.13542

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  5 in total

1.  Locomotor activity does not predict individual differences in morphine self-administration in rats.

Authors:  Yayi Swain; Peter Muelken; Mark G LeSage; Jonathan C Gewirtz; Andrew C Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-02-02       Impact factor: 3.533

2.  Enhanced fear memories and brain glucose metabolism (18F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats.

Authors:  Kennett D Radford; Thomas Y Park; Shalini Jaiswal; Hongna Pan; Andrew Knutsen; Michael Zhang; Mercedes Driscoll; Lisa A Osborne-Smith; Bernard J Dardzinski; Kwang H Choi
Journal:  Transl Psychiatry       Date:  2018-11-30       Impact factor: 6.222

3.  The effects of perinatal bisphenol A exposure on thyroid hormone homeostasis and glucose metabolism in the prefrontal cortex and hippocampus of rats.

Authors:  Xiaobin Xu; Shijun Fan; Yuanqiao Guo; Ruei Tan; Junyu Zhang; Wenhua Zhang; Bing-Xing Pan; Nobumasa Kato
Journal:  Brain Behav       Date:  2019-02-13       Impact factor: 2.708

4.  Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination.

Authors:  Dominique Vodovar; Adeline Duchêne; Catriona Wimberley; Claire Leroy; Géraldine Pottier; Yves Dauvilliers; Christian Giaume; Jian-Sheng Lin; Franck Mouthon; Nicolas Tournier; Mathieu Charvériat
Journal:  Int J Neuropsychopharmacol       Date:  2018-07-01       Impact factor: 5.176

5.  Optimizing clozapine for chemogenetic neuromodulation of somatosensory cortex.

Authors:  Jongwook Cho; Seungjun Ryu; Sunwoo Lee; Junsoo Kim; Hyoung-Ihl Kim
Journal:  Sci Rep       Date:  2020-04-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.